MRNA

#569
Moderna, Inc. Common Stock
53.50 USD
-1.40%
Сектор: Здравоохранение
Базовая: USD
Валюта прибыли: USD
Дневной диапазон
53.27
54.21
Годовой диапазон
22.29
59.55
Дневное изменение
-1.40%
Месячное изменение
0.00%
6-месячное изменение
+102.73%
Годовое изменение
+111.63%
Предыдущее закрытие
54.26
Открыть
54.13
Bid
Ask
Минимум
53.27
High
54.21
Объем
553
Открыть полный график

Financials

Обзор Отчетность Статистика
Квартал Год
  • Market Capitalization 21.13 B
  • Employee 4 700
  • Founded N/A
  • CEO Stéphane Bancel
  • Website www.modernatx.com
  • Headquarter Delaware, United States
  • FIGI BBG003PHHZT1
  • Industry Биотехнологии
Общий доход
Чистая прибыль
Базовая прибыль на акцию
Общий долг
Свободный денежный поток
Денежные средства и эквиваленты
Коэффициент цена/прибыль
-4.06
Коэффициент цена/денежный поток
5.9

Moderna Inc

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern". The company's commercial products are the Moderna COVID-19 vaccine, marketed as Spikevax and a respiratory syncytial virus vaccine, marketed as Mresvia. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.

Новости